Outpatient terlipressin infusion for the prevention of liver events in cirrhosis
Phase 3
Not yet recruiting
- Conditions
- cirrhosisOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
- Registration Number
- ACTRN12624000903583
- Lead Sponsor
- Austin Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Cirrhosis with ascites
Exclusion Criteria
Alcohol intake within 6 months
NHYA heart failure class III or IV
intrinsic renal disease eGFR <30
active cancer other than HCC within Milan
Terlipressin intolerance
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie terlipressin's efficacy in preventing liver decompensation in cirrhosis?
How does continuous terlipressin infusion compare to albumin in preventing hepatic decompensation events in cirrhotic patients?
Which biomarkers correlate with terlipressin response in cirrhosis patients with portal hypertension?
What adverse events are associated with long-term terlipressin use in cirrhosis management and how are they managed?
Are there synergistic effects of combining terlipressin with vasopressin receptor antagonists in cirrhosis treatment?